Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 3-50 (IGHV3-50)
- Target
- IGHV3-50
- Molecular classification
- Immunoglobulin gene segment, Variable region gene, Other (part of adaptive immune gene family)
01
Overview
Immunoglobulin heavy variable 3-50 (IGHV3-50) is a gene segment in the immunoglobulin heavy-chain locus encoding part of the variable region of antibody heavy chains in humans. It is used during V(D)J recombination in B cell development to create a diverse repertoire of antibodies, allowing the immune system to recognize a broad array of antigens[1][2][4]. IGHV3-50 is one of many highly polymorphic gene segments contributing to antibody diversity; its usage, mutation status, and allelic variants are relevant in immunology and as biomarkers in certain hematological malignancies but it is not a classic druggable target or immune receptor in itself.
- Other names
- 3-50PIGHV350IGHV3-50
02
Mechanism of action
Not applicable as a target. The gene segment encodes variable regions of antibodies; these antibodies can be engineered as therapeutics but IGHV3-50 itself is not modulated by drugs.
03
Biological functions
Antigen binding (via encoding antibody variable region)Generation of antibody diversity through V(D)J recombinationImmune response (adaptive immunity)
04
Disease associations
Cancer (especially as a biomarker in B cell malignancies, e.g. lymphomas, leukemias, where IGHV gene usage or mutation status is relevant[6])Infection (through involvement in antibody responses)Other (as a gene segment, not a direct disease driver, but its sequence usage can be related to disease prognosis)
05
Biomarkers
IGHV gene mutation status is a prognostic biomarker in B cell malignancies, such as chronic lymphocytic leukemia (CLL)[6].Specific IGHV gene segment usage can be tracked in minimal residual disease assays, immune repertoire analysis, or clonality assessments.
Beyond the preview
Go deeper on Immunoglobulin heavy variable 3-50 (IGHV3-50).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoglobulin heavy variable 3-50 (IGHV3-50).